Annual EBITDA
$1.00 B
+$103.39 M+11.52%
December 31, 2022
Summary
- As of March 8, 2025, HZNP annual EBITDA is $1.00 billion, with the most recent change of +$103.39 million (+11.52%) on December 31, 2022.
- During the last 3 years, HZNP annual EBITDA has risen by +$697.01 million (+229.26%).
Performance
HZNP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly EBITDA
$243.63 M
+$114.03 M+87.99%
June 30, 2023
Summary
- As of March 8, 2025, HZNP quarterly EBITDA is $243.63 million, with the most recent change of +$114.03 million (+87.99%) on June 30, 2023.
- Over the past year, HZNP quarterly EBITDA has increased by +$60.01 million (+32.68%).
Performance
HZNP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBITDA
$901.54 M
+$60.01 M+7.13%
June 30, 2023
Summary
- As of March 8, 2025, HZNP TTM EBITDA is $901.54 million, with the most recent change of +$60.01 million (+7.13%) on June 30, 2023.
- Over the past year, HZNP TTM EBITDA has dropped by -$325.52 million (-26.53%).
Performance
HZNP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
HZNP EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +11.5% | +32.7% | -26.5% |
3 y3 years | +229.3% | +156.0% | +175.8% |
5 y5 years | +1413.7% | +234.1% | +196.5% |
HZNP EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | -10.3% | -26.1% | -46.8% | -29.2% | -6.7% |
5 y | 5-year | at high | -69.6% | -42.6% | -135.6% | -29.2% | -66.4% |
alltime | all time | at high | -121.2% | -42.6% | -181.2% | -29.2% | -134.6% |
Horizon Therapeutics Public Limited EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2023 | - | $243.63 M(+88.0%) | $901.54 M(+7.1%) |
Mar 2023 | - | $129.60 M(-52.3%) | $841.53 M(-15.9%) |
Dec 2022 | $1.00 B(+11.5%) | $271.67 M(+5.9%) | $1.00 B(-5.5%) |
Sep 2022 | - | $256.64 M(+39.8%) | $1.06 B(-13.7%) |
Jun 2022 | - | $183.62 M(-36.5%) | $1.23 B(-3.7%) |
Mar 2022 | - | $289.11 M(-12.3%) | $1.27 B(+41.9%) |
Dec 2021 | $897.64 M(+21.2%) | $329.63 M(-22.4%) | $897.64 M(+2.2%) |
Sep 2021 | - | $424.70 M(+84.5%) | $878.62 M(+19.0%) |
Jun 2021 | - | $230.13 M(-365.1%) | $738.37 M(+22.4%) |
Mar 2021 | - | -$86.82 M(-128.0%) | $603.42 M(-18.5%) |
Dec 2020 | $740.71 M(+143.6%) | $310.61 M(+9.2%) | $740.71 M(+36.2%) |
Sep 2020 | - | $284.45 M(+198.9%) | $543.90 M(+66.4%) |
Jun 2020 | - | $95.18 M(+88.6%) | $326.87 M(+7.9%) |
Mar 2020 | - | $50.47 M(-55.7%) | $302.85 M(-0.4%) |
Dec 2019 | $304.02 M(+5.4%) | $113.80 M(+68.8%) | $304.02 M(-9.3%) |
Sep 2019 | - | $67.42 M(-5.3%) | $335.21 M(-14.7%) |
Jun 2019 | - | $71.16 M(+37.8%) | $393.01 M(-0.4%) |
Mar 2019 | - | $51.64 M(-64.4%) | $394.78 M(+36.9%) |
Dec 2018 | $288.32 M(-478.4%) | $144.99 M(+15.8%) | $288.32 M(+74.9%) |
Sep 2018 | - | $125.22 M(+71.7%) | $164.89 M(+94.6%) |
Jun 2018 | - | $72.93 M(-233.0%) | $84.73 M(-187.9%) |
Mar 2018 | - | -$54.82 M(-354.2%) | -$96.37 M(+26.5%) |
Dec 2017 | -$76.20 M(-193.5%) | $21.56 M(-52.1%) | -$76.20 M(-52.5%) |
Sep 2017 | - | $45.06 M(-141.7%) | -$160.28 M(-4.6%) |
Jun 2017 | - | -$108.16 M(+212.1%) | -$167.95 M(-813.1%) |
Mar 2017 | - | -$34.66 M(-44.6%) | $23.55 M(-71.1%) |
Dec 2016 | $81.46 M | -$62.52 M(-267.2%) | $81.46 M(-58.6%) |
Sep 2016 | - | $37.39 M(-55.1%) | $196.96 M(-20.7%) |
Jun 2016 | - | $83.34 M(+258.4%) | $248.40 M(+182.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2016 | - | $23.25 M(-56.1%) | $88.06 M(+16.6%) |
Dec 2015 | $75.53 M(-135.7%) | $52.98 M(-40.4%) | $75.53 M(+415.4%) |
Sep 2015 | - | $88.84 M(-215.4%) | $14.66 M(-123.2%) |
Jun 2015 | - | -$77.01 M(-817.9%) | -$63.14 M(+1768.1%) |
Mar 2015 | - | $10.73 M(-235.8%) | -$3.38 M(-98.4%) |
Dec 2014 | -$211.85 M(+65.5%) | -$7.90 M(-171.5%) | -$211.85 M(-29.7%) |
Sep 2014 | - | $11.04 M(-164.0%) | -$301.41 M(-3.4%) |
Jun 2014 | - | -$17.25 M(-91.3%) | -$312.09 M(+1.2%) |
Mar 2014 | - | -$197.75 M(+102.9%) | -$308.26 M(+140.7%) |
Dec 2013 | -$128.04 M(+68.8%) | -$97.45 M(<-9900.0%) | -$128.04 M(+142.1%) |
Sep 2013 | - | $357.00 K(-102.7%) | -$52.90 M(-24.3%) |
Jun 2013 | - | -$13.42 M(-23.4%) | -$69.87 M(-7.0%) |
Mar 2013 | - | -$17.53 M(-21.4%) | -$75.14 M(-1.0%) |
Dec 2012 | -$75.88 M(-35.4%) | -$22.31 M(+34.2%) | -$75.88 M(-46.8%) |
Sep 2012 | - | -$16.62 M(-11.1%) | -$142.71 M(+1.4%) |
Jun 2012 | - | -$18.69 M(+2.3%) | -$140.72 M(+8.5%) |
Mar 2012 | - | -$18.26 M(-79.5%) | -$129.75 M(+10.9%) |
Dec 2011 | -$117.47 M(+440.6%) | -$89.14 M(+509.4%) | -$117.04 M(+475.3%) |
Sep 2011 | - | -$14.63 M(+89.4%) | -$20.34 M(+21.7%) |
Jun 2011 | - | -$7.72 M(+39.1%) | -$16.72 M(+4155.2%) |
Mar 2011 | - | -$5.55 M(-173.5%) | -$393.00 K(-83.3%) |
Dec 2010 | -$21.73 M(+16.1%) | $7.55 M(-168.7%) | -$2.35 M(-84.9%) |
Sep 2010 | - | -$11.01 M(-227.8%) | -$15.58 M(+78.3%) |
Jun 2010 | - | $8.61 M(-214.6%) | -$8.74 M(-59.8%) |
Mar 2010 | - | -$7.51 M(+32.3%) | -$21.74 M(+19.8%) |
Dec 2009 | -$18.71 M(-30.3%) | -$5.67 M(+36.4%) | -$18.16 M(+45.5%) |
Sep 2009 | - | -$4.16 M(-5.3%) | -$12.48 M(+50.0%) |
Jun 2009 | - | -$4.39 M(+12.0%) | -$8.32 M(+112.0%) |
Mar 2009 | - | -$3.92 M | -$3.92 M |
Dec 2008 | -$26.83 M | - | - |
FAQ
- What is Horizon Therapeutics Public Limited annual EBITDA?
- What is the all time high annual EBITDA for Horizon Therapeutics Public Limited?
- What is Horizon Therapeutics Public Limited annual EBITDA year-on-year change?
- What is Horizon Therapeutics Public Limited quarterly EBITDA?
- What is the all time high quarterly EBITDA for Horizon Therapeutics Public Limited?
- What is Horizon Therapeutics Public Limited quarterly EBITDA year-on-year change?
- What is Horizon Therapeutics Public Limited TTM EBITDA?
- What is the all time high TTM EBITDA for Horizon Therapeutics Public Limited?
- What is Horizon Therapeutics Public Limited TTM EBITDA year-on-year change?
What is Horizon Therapeutics Public Limited annual EBITDA?
The current annual EBITDA of HZNP is $1.00 B
What is the all time high annual EBITDA for Horizon Therapeutics Public Limited?
Horizon Therapeutics Public Limited all-time high annual EBITDA is $1.00 B
What is Horizon Therapeutics Public Limited annual EBITDA year-on-year change?
Over the past year, HZNP annual EBITDA has changed by +$103.39 M (+11.52%)
What is Horizon Therapeutics Public Limited quarterly EBITDA?
The current quarterly EBITDA of HZNP is $243.63 M
What is the all time high quarterly EBITDA for Horizon Therapeutics Public Limited?
Horizon Therapeutics Public Limited all-time high quarterly EBITDA is $424.70 M
What is Horizon Therapeutics Public Limited quarterly EBITDA year-on-year change?
Over the past year, HZNP quarterly EBITDA has changed by +$60.01 M (+32.68%)
What is Horizon Therapeutics Public Limited TTM EBITDA?
The current TTM EBITDA of HZNP is $901.54 M
What is the all time high TTM EBITDA for Horizon Therapeutics Public Limited?
Horizon Therapeutics Public Limited all-time high TTM EBITDA is $1.27 B
What is Horizon Therapeutics Public Limited TTM EBITDA year-on-year change?
Over the past year, HZNP TTM EBITDA has changed by -$325.52 M (-26.53%)